1. Home
  2. ICCC vs AADI Comparison

ICCC vs AADI Comparison

Compare ICCC & AADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICCC
  • AADI
  • Stock Information
  • Founded
  • ICCC 1982
  • AADI 2011
  • Country
  • ICCC United States
  • AADI United States
  • Employees
  • ICCC N/A
  • AADI N/A
  • Industry
  • ICCC Biotechnology: Pharmaceutical Preparations
  • AADI Biotechnology: Pharmaceutical Preparations
  • Sector
  • ICCC Health Care
  • AADI Health Care
  • Exchange
  • ICCC Nasdaq
  • AADI Nasdaq
  • Market Cap
  • ICCC 35.4M
  • AADI 33.6M
  • IPO Year
  • ICCC 1987
  • AADI N/A
  • Fundamental
  • Price
  • ICCC $4.16
  • AADI $1.43
  • Analyst Decision
  • ICCC
  • AADI Buy
  • Analyst Count
  • ICCC 0
  • AADI 2
  • Target Price
  • ICCC N/A
  • AADI $5.00
  • AVG Volume (30 Days)
  • ICCC 6.0K
  • AADI 325.1K
  • Earning Date
  • ICCC 08-08-2024
  • AADI 08-07-2024
  • Dividend Yield
  • ICCC N/A
  • AADI N/A
  • EPS Growth
  • ICCC N/A
  • AADI N/A
  • EPS
  • ICCC N/A
  • AADI N/A
  • Revenue
  • ICCC $21,282,719.00
  • AADI $23,840,000.00
  • Revenue This Year
  • ICCC N/A
  • AADI $4.21
  • Revenue Next Year
  • ICCC N/A
  • AADI $8.61
  • P/E Ratio
  • ICCC N/A
  • AADI N/A
  • Revenue Growth
  • ICCC 32.89
  • AADI 26.97
  • 52 Week Low
  • ICCC $4.05
  • AADI $1.28
  • 52 Week High
  • ICCC $5.75
  • AADI $7.24
  • Technical
  • Relative Strength Index (RSI)
  • ICCC 42.25
  • AADI 42.41
  • Support Level
  • ICCC $4.10
  • AADI $1.46
  • Resistance Level
  • ICCC $4.29
  • AADI $1.69
  • Average True Range (ATR)
  • ICCC 0.11
  • AADI 0.11
  • MACD
  • ICCC -0.00
  • AADI 0.02
  • Stochastic Oscillator
  • ICCC 13.04
  • AADI 36.67

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

About AADI Aadi Bioscience Inc.

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Share on Social Networks: